Saluda Medical Evoke SCS System
Saluda Medical Pty, Ltd. · Decision date Jun 12, 2026
What did the FDA decide?
FDA records P190002/S049 as a supplement to PMA P190002, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 12, 2026.
FDA approval order statement
to transition to a new Ethylene Oxide (EO) sterilizer, add additional monitoring system to record temperature and pressure throughout cycle, improve control panel with touch screen digital panel, and add an alternate load configuration
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Jun 12, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P190002/S049
- Regulatory pathway
- PMA supplement
- Applicant
- Saluda Medical Pty, Ltd.
- Product code
- LGW
- Decision code
- OK30
- Decision date
- Jun 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Saluda Medical Pty, Ltd.
- Product code
- LGW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P190002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P190002 · Original PMA
Saluda Medical Evoke SCS System
P190002/S041 · Related supplement
Saluda Medical Evoke SCS System
P190002/S045 · Related supplement
Saluda Medical Evoke SCS System
P190002/S036 · Related supplement
Saluda Medical Evoke SCS System
P190002/S049 received
Application receipt date recorded by FDA.
P190002/S048 · Related supplement
Evoke SCS System
P190002/S049 · FDA decision
30-Day Notice
P190002/S038 · Related supplement
Saluda Medical Evoke SCS System; Closed Loop Stimulator (CLS) (REF: 3042)
P190002/S039 · Related supplement
CAP24 Paddle Lead, Passing Elevator, Evoke CLS (REF 3042), Clarity Programming Application (CPA), and RECAP Viewer
P190002/S051 · Related supplement
Saluda Medical Evoke SCS System
P190002/S052 · Related supplement
Saluda Medical Evoke SCS System
Timeline entries are records held by MedtechLedger for P190002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Saluda Medical Pty, Ltd. | PMA approval | Feb 28, 2022 | FDA | |
Saluda Medical Evoke SCS SystemP190002/S041 | Saluda Medical Pty, Ltd. | PMA supplement | Aug 21, 2025 | FDA |
Saluda Medical Evoke SCS SystemP190002/S045 | Saluda Medical Pty, Ltd. | PMA supplement | Nov 8, 2025 | FDA |
Saluda Medical Evoke SCS SystemP190002/S036 | Saluda Medical Pty, Ltd. | PMA supplement | Jan 6, 2026 | FDA |
Evoke SCS SystemP190002/S048 | Saluda Medical Pty, Ltd. | PMA supplement | Jun 12, 2026 | FDA |
| Saluda Medical Pty, Ltd. | PMA supplement | Jun 29, 2026 | FDA | |
| Saluda Medical Pty, Ltd. | PMA supplement | Jun 29, 2026 | FDA | |
Saluda Medical Evoke SCS SystemP190002/S051 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 15, 2026 | FDA |
Saluda Medical Evoke SCS SystemP190002/S052 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Saluda Medical Pty, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Level 1, 407 Pacific Hwy., Atarmon, NSW 2064
Sources and methodology
- Original FDA record: P190002/S049
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





